stoxline Quote Chart Rank Option Currency Glossary
Fortress Biotech, Inc. (FBIO)
3.3  0.5 (17.86%)    12-07 16:00
Open: 2.84
High: 3.5
Volume: 1,117,262
Pre. Close: 2.8
Low: 2.82
Market Cap: 49(M)
Technical analysis
2023-12-07 4:20:32 PM
Short term     
Mid term     
Targets 6-month :  4.08 1-year :  4.77
Resists First :  3.5 Second :  4.08
Pivot price 2.3
Supports First :  2.1 Second :  1.24
MAs MA(5) :  2.71 MA(20) :  2.1
MA(100) :  4.64 MA(250) :  8.15
MACD MACD :  0 Signal :  -0.1
%K %D K(14,3) :  91.4 D(3) :  86.1
RSI RSI(14): 66
52-week High :  17.39 Low :  1.24
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ FBIO ] has closed above the upper band by 6.6%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 14.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.5 - 3.51 3.51 - 3.52
Low: 2.79 - 2.8 2.8 - 2.82
Close: 3.28 - 3.3 3.3 - 3.32
Company Description

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.

Headline News

Thu, 07 Dec 2023
Healthcare Stocks on the Move Thursday: SLDB, UPC, SYRS, FBIO, ZVSA, WVE, OMER, SERA - InvestorsObserver

Thu, 07 Dec 2023
Can Fortress Biotech Inc (FBIO) Stock Rise to the Top of Healthcare Sector Thursday? - InvestorsObserver

Wed, 06 Dec 2023
Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper ... - Yahoo Finance

Fri, 01 Dec 2023
Is Fortress Biotech Inc (FBIO) a Bad Choice in Biotechnology Friday? - InvestorsObserver

Fri, 17 Nov 2023
Fortress Biotech Third Quarter 2023 Earnings: Beats Expectations - Simply Wall St

Tue, 14 Nov 2023
Fortress Biotech: Q3 Earnings Snapshot - Houston Chronicle

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 15 (M)
Shares Float 6 (M)
Held by Insiders 0 (%)
Held by Institutions 0 (%)
Shares Short 260 (K)
Shares Short P.Month 92 (K)
Stock Financials
EPS -11.35
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.87
Profit Margin -126.4 %
Operating Margin -208 %
Return on Assets (ttm) -51 %
Return on Equity (ttm) -414.6 %
Qtrly Rev. Growth -4.7 %
Gross Profit (p.s.) 0
Sales Per Share 4.17
EBITDA (p.s.) -12.57
Qtrly Earnings Growth 0 %
Operating Cash Flow -141 (M)
Levered Free Cash Flow -89 (M)
Stock Valuations
PE Ratio -0.3
PEG Ratio -0.1
Price to Book value 1.76
Price to Sales 0.78
Price to Cash Flow -0.35
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android